What the research found
Large observational studies in people with type 2 diabetes and obesity show that those using GLP-1 drugs develop fewer weight-related cancers than comparison groups. A 2024 analysis of 1.6 million people with diabetes found lower incidence of cancers including pancreatic, liver, endometrial, ovarian, and colorectal. A 2025 study of roughly 87,000 people with obesity reported a 17% lower overall cancer rate in GLP-1 users, with particularly strong reductions in endometrial (25% lower) and ovarian cancer (47% lower).
When researchers compared GLP-1 use directly against metformin—another metabolic drug with its own anti-cancer associations—most of the GLP-1 advantage disappeared. This suggests that improving metabolic control, rather than something unique to GLP-1s, may be driving the benefit. An interesting wrinkle: one study found GLP-1 users had lower cancer risk than people who underwent bariatric surgery despite losing less weight, hinting that factors beyond weight loss alone may be at play.
A separate analysis of people diagnosed with early-stage cancer found that those on GLP-1 drugs were 38–50% less likely to progress to metastatic disease compared to those on older diabetes medications, across several cancer types.
Why it matters for you
If you're tracking weight, blood glucose, and inflammatory markers on MyKine while using a GLP-1, these findings reframe what the drug might be doing. The data suggest metabolic health—not just the number on the scale—correlates with cancer risk. That means your fasting glucose, insulin levels, and inflammatory biomarkers (if you track them) may matter as much as weight loss itself for whatever protective signal exists here.
The more intriguing signal is in people who already have cancer. If you or someone close to you has navigated an early cancer diagnosis, the question isn't "should I take this to prevent cancer"—it's whether metabolic control during active disease or treatment might influence progression. That's preliminary, but it's a different claim than prevention.
One practical note: the kidney cancer signal appearing twice across independent datasets deserves monitoring. It trended higher in GLP-1 users in both studies, though the effect wasn't always statistically clear. This is worth flagging with your doctor if you have personal or family history of kidney cancer.
Caveats
- Observational only: People prescribed GLP-1s may differ in unmeasured ways (healthcare access, screening frequency, socioeconomic status, diet quality). These studies cannot prove the drug caused the difference.
- Metformin comparison is telling: When a similar metabolic drug performs similarly, it weakens the case for something unique about GLP-1s.
- Bariatric surgery comparison is small and preliminary: Only one study made this head-to-head comparison.
- Cancer progression data are conference abstracts: Not yet peer-reviewed; details may change in formal publication.
- Kidney cancer signal is unresolved: Appears in multiple studies but isn't statistically definitive; biological mechanism unknown.
- No approved indication: Retatrutide isn't approved for any indication yet, and using unapproved research chemicals carries obvious safety unknowns.